Dofamin (dopamine hydrochloride) concentrate for infusions 5 mg/ml. 5 ml. ampoules №10


Manufacturer: India

Shock States or States that threaten the occurrence of shock: heart failure caused by acute myocardial infarction (cardiogenic shock); severe infections (infectious and toxic shock); state of shock after operations; marked decrease in blood pressure (severe hypotension) of any origin; hypersensitivity reactions (anaphylactic shock).



Dofamin Composition

active ingredient 1 ml of concentrate contains dopamine hydrochloride – 5 mg or 40 mg
excipients: sodium metabisulfite (E 223), diluted hydrochloric acid, water for injection.

Dofamin Dosage form

Concentrate for preparation of solution for infusion.

Basic physical and chemical properties:

transparent colorless or slightly yellowish liquid.

Dofamin Pharmacological group

Non-glycosidic cardiotonic drugs. Adrenergic and dopaminergic drugs. ATX code С01С А04.

Pharmacological properties


After stopping the administration, the effect lasts no more than 5-10 minutes


Since dopamine is a natural intermediate in the synthesis of norepinephrine, it is impossible to track its pharmacokinetics in the body in most cases.

After administration, the half-life (T 1/2) is up to 5 minutes (on average 2 minutes). It is metabolized in almost all tissues. 75% of the administered dose is excreted from the body during the first day by the kidneys in the form of inactive metabolites. Up to 25% of the introduced dopamine by the mechanism of reuptake into the neurovesicles is used for the synthesis of norepinephrine. The onset of action is within 5 minutes after the start of the administration, the end is 5-10 minutes after the termination of the infusion.


Conditions of shock or conditions that threaten the occurrence of shock:

heart failure caused by acute myocardial infarction (cardiogenic shock)
severe infections (infectious toxic shock)
state of shock after surgery
marked decrease in blood pressure (severe hypotension) of any genesis
hypersensitivity reactions (anaphylactic shock).


Hypersensitivity to dopamine or other components of the drug.

Pheochromocytoma, thyrotoxicosis.

Tachyarrhythmia, ventricular fibrillation, as well as conditions that are accompanied by mechanical resistance to filling the ventricles.

Hypovolemia (before starting treatment, it is necessary to restore the deficit in circulating blood volume).


Hyperplasia of the prostate with urinary retention.

Anesthesia with cyclopropane and halogenated hydrocarbons should be avoided.

Interaction with other medicinal products and other forms of interaction

Sympathomimetics, guanethidine – the sympathomimetic effect of Dopamine-Darnitsa is enhanced.

MAO inhibitors (MAO) potentiate the effects of dopamine and prolong the effect of the drug. With great caution, dopamine should be used to treat patients taking MAO inhibitors or within the past 2 weeks. Such patients should be prescribed a significantly lower dose of dopamine (starting dose – 1/10 of the usual therapeutic dose).

Tricyclic antidepressants and maprotiline. Dopamine increases the amount of norepinephrine released in the nerve endings. Tricyclic antidepressants inhibit the reuptake of norepinephrine in nerve endings and thereby potentiate the effects of dopamine. For patients taking antidepressants, the dose of dopamine should be reduced due to the potentiation of the effects.